faricimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5515	1607793-29-2

Description:

Molecule	Description
Molfile Synonyms: faricimab faricimab-svoa vabysmo RO6867461 RG7716 faricimab (genetical recombination)	Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD and DME. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD and DME has yet to be established. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

faricimab
faricimab-svoa
vabysmo
RO6867461
RG7716
faricimab (genetical recombination)

Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD and DME. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD and DME has yet to be established.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Sept. 15, 2022	EMA	ROCHE REGISTRATION GMBH
Jan. 28, 2022	FDA	GENENTECH INC
March 28, 2022	PMDA	Chugai Pharmaceutical Co., Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01LA09	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
MeSH PA	D020533	Angiogenesis Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Macular edema due to diabetes mellitus	indication	312912001	DOID:9191
Exudative age-related macular degeneration	indication	414173003	DOID:10873
Uveitis	contraindication	128473001	DOID:13141
Ocular or periocular infection	contraindication	715266002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vascular endothelial growth factor A	Secreted	P15692	VEGFA_HUMAN	BINDING AGENT	Kd	8.76		DRUG LABEL	DRUG LABEL
Angiopoietin-2	Secreted	O15123	ANGP2_HUMAN	BINDING AGENT	Kd	7.70		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4297750	ChEMBL_ID
C000723200	MESH_SUPPLEMENTAL_RECORD_UI
11420	IUPHAR_LIGAND_ID
DB15303	DRUGBANK_ID
018943	NDDF
4041143	VANDF
4041144	VANDF
C5139890	UMLSCUI
D11516	KEGG_DRUG
10563	INN_ID
91827367	PUBCHEM_CID
2591519	RXNORM
358850	MMSL
40656	MMSL
QC4F7FKK7I	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VABYSMO	HUMAN PRESCRIPTION DRUG LABEL	1	50242-096	INJECTION, SOLUTION	6 mg	INTRAVITREAL	BLA	28 sections
VABYSMO	HUMAN PRESCRIPTION DRUG LABEL	1	50242-096	INJECTION, SOLUTION	6 mg	INTRAVITREAL	BLA	28 sections